Kristen Stewart has indicated she will probably not remain in the United States amid Donald Trump's return to the presidency.

In a recent interview with *The Sunday Times* (also referenced in reports as *The Times*), the actress and first-time director voiced strong concerns over Trump's proposed 100% tariff on films produced outside the U.S., which she described as "terrifying" for the industry. Stewart, who shot her directorial debut *The Chronology of Water* in Latvia because she felt it would have been "impossible" to make in the States, cited an inability to work freely in America and a desire for greater creative independence.

She described the current Hollywood environment as part of a broader "capitalist hell" that imposes barriers, particularly for marginalized voices, and stated that "reality is breaking completely under Trump." While she has no intention of fully abandoning American audiences, Stewart expressed plans to base her filmmaking career more in Europe, saying she wants to "make movies in Europe and then shove them down the throat of the American people."

Stewart, who splits her time between Los Angeles and New York, emphasized she doesn't want to "give up completely" on the U.S. but sees moving abroad as necessary for the creative freedom she seeks. Her comments reflect ongoing tensions in the film industry following Trump's policy proposals aimed at prioritizing domestic production.

Metastases Spinal Tumor Market Forecast: Rising Cancer Burden Fuels Demand

According to a newly published market research report by 24LifeSciences, global Metastases Spinal Tumor market value is at USD 1,085 million in 2026 and is projected to reach USD 1,409 million by 2034, growing at a compound annual growth rate (CAGR) of 3.9% during the forecast period.

Metastatic spinal tumors are secondary malignant growths originating from cancer that has spread (metastasized) from other parts of the body to the spine. This condition represents a significant clinical challenge, as more than 95% of all metastatic spinal tumors are found outside the dura (extradural) and within the vertebral body. Furthermore, these tumors are often present at multiple spinal levels, complicating treatment. The spine is the most common site for bone metastases, with cells typically reaching it via the bloodstream before proliferating in the bone marrow.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9532/metastases-spinal-tumor-market

Hydrolyzed Sclerotium Gum Market Size & Forecast: Cosmetics & Skin Care Trends

Hydrolyzed sclerotium gum is valued for its exceptional water-binding capacity, skin feel enhancement properties, and compatibility with various formulation systems. .

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/276423/global-hydrolyzed-sclerotium-gum-market-2024-599

FibroTouch Devices Market Size to Reach USD 220 Million by 2032 | Growth Insights

Global FibroTouch Devices market is undergoing steady expansion as healthcare systems increasingly prioritize non-invasive diagnostics for liver disease management. Valued at USD 120 million in 2024, the market is projected to grow from USD 132 million in 2025 to USD 220 million by 2032, registering a CAGR of 7.8% during the forecast period. This growth reflects a structural shift away from invasive liver biopsies toward faster, safer, and more patient-friendly elastography-based solutions that deliver real-time clinical insights.
The FibroTouch Devices market is gaining prominence across hospitals, diagnostic centers, and specialty clinics as chronic liver conditions such as NAFLD, viral hepatitis, and alcoholic liver disease continue to rise globally. Increasing disease awareness, early screening initiatives, and technological refinements are positioning FibroTouch as a core diagnostic modality in modern hepatology workflows.

Access the market report https://www.24lifesciences.com/fibrotouch-devices-market-9969

Tardive Dyskinesia Treatment Market Size to Reach USD 1.3 Billion by 2032 | Growth Insights

Global Tardive Dyskinesia Treatment market is undergoing a notable transformation as healthcare systems prioritize early diagnosis, neurological specialization, and precision pharmacotherapy. Valued at USD 643.5 million in 2024, the market is projected to grow from USD 720.6 million in 2025 to USD 1.3 billion by 2032, expanding at a CAGR of 9.2% during the forecast period. Rising awareness of movement disorders, increased use of long-term antipsychotic therapies, and the growing adoption of FDA-approved VMAT2 inhibitors are central to this sustained growth trajectory.

Access the market report https://www.24lifesciences.com/tardive-dyskinesia-treatment-market-10341

Dental CBCT Scan Market Size to Reach USD 1.96 Billion by 2032 | Growth Insights & Forecasts

Global Dental CBCT scan market is undergoing sustained expansion as dentistry rapidly transitions toward precision-driven, digital diagnostic workflows. Valued at USD 1.14 billion in 2024, the market is projected to grow from USD 1.24 billion in 2025 to reach USD 1.96 billion by 2032, registering a CAGR of 6.7% over the forecast period. Increasing demand for implantology, orthodontics, and minimally invasive oral surgery is positioning CBCT technology as a cornerstone of modern dental diagnostics.

Access the market report https://www.24lifesciences.com/dental-cbct-scan-market-9779

Patient Derived Xenograft (PDX) Models Market Size to Reach USD 653 Million by 2032

Global Patient Derived Xenograft (PDX) Models market is witnessing strong momentum as precision oncology and personalized medicine reshape cancer drug development worldwide. Valued at USD 358 million in 2024, the market is projected to reach USD 653 million by 2032, expanding at a robust CAGR of 9.2% during the forecast period. Increasing demand for highly predictive preclinical models, coupled with rising oncology R&D investment, continues to position PDX models as a cornerstone of modern translational cancer research.

Access the market report https://www.24lifesciences.com/patient-derived-xenograft-pdx-models-market-9495

Mendelian Disorders Testing Market Size to Reach USD 7.8 Billion by 2032 | Growth Trends & Insights

Global Mendelian disorders testing market is gaining strong momentum as healthcare systems worldwide intensify their focus on early diagnosis, preventive screening, and precision medicine. The market is projected to expand from USD 4.6 billion in 2025 to USD 7.8 billion by 2032, registering a robust compound annual growth rate (CAGR) of 7.8% during the forecast period. This sustained growth reflects rising awareness of inherited diseases, expanding newborn and prenatal screening programs, and rapid advancements in genomic testing technologies.

Access the market report https://www.24lifesciences.com/mendelian-disorders-testing-market-9526

Oral Thrush Market Size to Reach USD 8.52 Billion by 2032 | Growth Trends & Forecasts

Global Oral Thrush market continues to demonstrate steady expansion, supported by rising awareness of fungal infections, improved access to antifungal therapies, and increasing prevalence of immunocompromising conditions worldwide. Valued at USD 7.11 billion in 2024, the market is projected to grow from USD 7.29 billion in 2025 to USD 8.52 billion by 2032, registering a CAGR of 2.7% over the forecast period. Sustained demand from vulnerable populations and consistent treatment needs underpin the market’s long-term stability.

Access the market report https://www.24lifesciences.com/oral-thrush-market-9566

Metabolic Biomarker Testing Market Size to Reach USD 22.8 Billion by 2032 | Growth Trends & Forecasts

Global metabolic biomarker testing market is experiencing robust growth as healthcare systems increasingly prioritize precision diagnostics, early disease detection, and individualized treatment strategies. Valued at USD 11.3 billion in 2024, the market is expected to expand from USD 12.5 billion in 2025 to USD 22.8 billion by 2032, registering a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period. This strong trajectory highlights the growing clinical and commercial importance of metabolic biomarkers in modern healthcare and life sciences.

Access the market report https://www.24lifesciences.com/metabolic-biomarker-testing-market-9530

Non-Destructive Medical Technologies Market Size to Reach USD 9.41 Billion by 2032

Global Non-Destructive Medical Technologies market is undergoing steady and technology-driven expansion, reflecting the healthcare sector’s growing reliance on safe, accurate, and minimally invasive diagnostic solutions. Valued at USD 6.82 billion in 2024, the market is projected to reach USD 9.41 billion by 2032, advancing at a CAGR of 5.9% during the forecast period. This growth trajectory is supported by the broader expansion of the global medical devices ecosystem, which continues to prioritize diagnostic precision, patient safety, and workflow efficiency across clinical settings.

Access the market report https://www.24lifesciences.com/non-destructive-medical-technologies-market-9555

Meningitis Diagnosis and Treatment Market Size to Reach USD 5.12 Billion by 2032 | Key Trends & Forecasts

Global meningitis diagnosis and treatment market is undergoing a pivotal transformation driven by heightened infectious disease vigilance, rapid adoption of molecular diagnostics, and expanding access to emergency clinical care. Valued at USD 3.02 billion in 2024, the market is projected to rise to USD 3.26 billion in 2025 and further reach USD 5.12 billion by 2032, growing at a CAGR of 6.8%. This reflects the global push toward faster pathogen detection, improved treatment regimens, and stronger public health infrastructure.

Access the complete dataset, competitive insights, and expert forecasts at 24LifeSciences. https://www.24lifesciences.com/meningitis-diagnosis-and-treatment-market-9528